Skip to main content

​Microbiome analysis company Bio-Me inks biomarker deal with one of the top 10 consumer healthcare companies worldwide

Press Release   •   Jan 18, 2019 13:57 GMT

Team Bio-Me at Oslo Science Park

Bio-Me AS using proprietary custom-made microbiome test to analyze samples from NTNU’s HUNT BioBank


Bio-Me, a pioneer in rapid gut microbiome analysis, has entered into an agreement with one of the top 10 consumer healthcare companies worldwide using  Bio-Me’s Precision Microbiome Profiling (PMP) platform and the  HUNT BioBank to identify gut microbiome biomarkers for a specific health condition.

The  Bio-Me PMP platform makes high-throughput quantification of multiple bacterial species and strains for hundreds of samples in less than a day. In addition,  Bio-Me has an agreement with  HUNT Research Center in Norway, giving the company access to both samples and health data from the 15,000 to 20,000 people contributing fecal samples to the ongoing  HUNT 4 study  The combination of fecal samples from such a large cohort, extensive medical information about each subject and Bio-Me’s PMP platform will bring important new insights into the specific health condition covered by this agreement.

Bio-Me CEO Morten L. Isaksen commented:

“We are delighted to sign this, our first well-funded commercial agreement with a major consumer healthcare company associated with the HUNT4 Study. Our partner’s continued interest and support shows that our PMP platform can assist the Pharma and Food industry alike. Both industry and the scientific community needed a rapid standardized discovery method for identifying important microbiome biomarkers and profiles. With PMP we can do in days what took months, allowing both communities to make life changing discoveries.”

Christian Jonasson, Industry Coordinator at  HUNT added:

"The decision HUNT took three years ago to include fecal sampling in the HUNT4 study was a strategic move made in order to stay up to date and to advance biobank precision medicine initiatives beyond genomics. We are thrilled to see this now manifested into concrete research activities. Our collaboration with Bio-Me is a good example of a successful public-private partnership as Bio-Me will perform all the analysis and return the data for free to HUNT databank enabling immediate access to academic researchers, while at the same time securing Bio-Me the proper commercial rights.”

Notes to Editors

Bio-Me has developed a microbiome profiling platform (PMP) that is transforming what is possible in precision medicine and personalized nutrition. The collaboration with HUNT, other BioBanks worldwide, and Bio-Me’s extensive microbiome database will enable drug discovery and companion diagnostics to improve health and well-being worldwide. The company is located at Oslo Science Park, Oslo, Norway.

Contact: Morten Isaksen, +47 97 51 20 70, m.isaksen@bio-me.nowww.bio-me.no


The Nord-Trøndelag Health Study (The HUNT Study) , owned and governed by the Norwegian University of Science and Technology (NTNU) is one of the largest health studies ever performed. It is a unique database of questionnaire data, clinical measurements and samples from a county in central Norway. The HUNT Research Centre has a database with information on 140,000 people recruited in four rounds since the mid 1980-ies. Approximately 300 national and international research projects are currently using the samples and data from HUNT’s collection.

Aleap, a non-profit incubator, offers a community for health startups. Our mission is to facilitate innovation and value creation by developing an ecosystem for ambitious health entrepreneurs and companies to create new products better and faster. We do this by offering a broad range of critical know-how, expertise, infrastructure and international business networks.

We believe that entrepreneurship and successful startups will benefit from collaboration in a multidisciplinary environment with proactive sharing.

Attached Files

PDF document